Management of Cutaneous Herpes Zoster in Patients Receiving Tofacitinib

Immediate Management

Discontinue tofacitinib immediately upon diagnosis of herpes zoster and do not restart until all cutaneous lesions have fully resolved (typically 15–22 days after onset). This recommendation is based on data from randomized controlled trials of tofacitinib in rheumatoid arthritis and psoriatic arthritis patients. 1, 2, 3
Start oral valacyclovir 1 g three times daily for 7 days, initiating therapy within 48–72 hours of rash onset for maximal antiviral efficacy. Prompt antiviral treatment reduces the risk of complications and accelerates lesion healing. 1, 2, 3
The increased risk of herpes zoster with JAK inhibition is mechanistically linked to blockade of interferon‑mediated antiviral pathways, which are essential for viral clearance. Understanding this mechanism supports the need for rapid drug interruption and antiviral therapy. 1, 2

When antiviral therapy has been started and acute symptoms are controlled, tofacitinib may be resumed earlier than the usual 15‑day waiting period, provided that lesions are crusted and pain has subsided. Early re‑initiation has been shown to be safe in trial participants who received concurrent antiviral treatment. 3

For patients experiencing a second (recurrent) herpes zoster episode while on tofacitinib, long‑term antiviral prophylaxis with valacyclovir should be strongly considered when the drug is restarted. This strategy aims to lower the observed 8 % recurrence rate in rheumatoid arthritis and 2.8 % in psoriatic arthritis cohorts. 1, 2
Administer the two‑dose recombinant zoster vaccine (Shingrix) after complete resolution of the acute episode, waiting at least 2 months before vaccination. Post‑episode vaccination provides additional protection against future herpes zoster events. 1, 2, 4
Shingrix is preferred over the live‑attenuated Zostavax vaccine for patients on or planning to resume tofacitinib; the live vaccine is contraindicated due to the immunosuppressive effect of JAK inhibition. This recommendation aligns with current rheumatology vaccination guidance. 1, 2, 4
Ideally, Shingrix should be administered before initiating tofacitinib therapy, but vaccination after a herpes zoster episode still confers protective immunity. Evidence from observational studies supports the benefit of post‑treatment vaccination. 4, 5

Never continue tofacitinib during active herpes zoster infection, as ongoing JAK inhibition impairs interferon‑mediated viral clearance and heightens the risk of severe or disseminated disease. This principle is reinforced by mechanistic and clinical trial data. 1, 2, 3